Renalytix Plc (LON:RENX) Insider Acquires £2,250 in Stock

Renalytix Plc (LON:RENXGet Free Report) insider James Renwick McCullough acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average price of GBX 9 ($0.11) per share, with a total value of £2,250 ($2,839.83).

James Renwick McCullough also recently made the following trade(s):

  • On Thursday, December 5th, James Renwick McCullough acquired 53,300 shares of Renalytix stock. The shares were purchased at an average cost of GBX 8 ($0.10) per share, for a total transaction of £4,264 ($5,381.80).

Renalytix Stock Down 3.7 %

RENX stock opened at GBX 9.15 ($0.12) on Friday. The company has a 50 day moving average price of GBX 7.76 and a two-hundred day moving average price of GBX 11.23. The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53. The stock has a market capitalization of £15.18 million, a P/E ratio of -38.13 and a beta of 2.10. Renalytix Plc has a one year low of GBX 6.50 ($0.08) and a one year high of GBX 74.90 ($0.95).

About Renalytix

(Get Free Report)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.

Featured Articles

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.